Interaction of HLA-DRB1*1501 allele and TNF-alpha -308 G/A single nucleotide polymorphism in the susceptibility to multiple sclerosis

Clinical Immunology

Volumn 139, Issue 3, 2011, Pages 277-281

  Shahbazi, Majid ^a   Roshandel, Danial ^a   omidnyia, Eskandar ^b   Rshaidbaghan, Azam ^a  

^a Gorgan University of Medical Science   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Gene gene interaction; Genetic susceptibility; ; HLA DRB1*1501; ; Multiple sclerosis; ; Tumor necrosis factor alpha;

Indexed keywords

GENOMIC DNA; HLA DR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA DETERMINATION; FEMALE; GENE; GENE INTERACTION; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HLA-DR ANTIGENS; HUMANS; IRAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79955970915     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.02.012     Document Type: Article

References (50)

1. Grytten N., Glad S.B., Aarseth J.H., Nyland H., Midgard R., Myhr K.M. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 2006, 66:182-186.
2. Alshubaili A.F., Alramzy K., Ayyad Y.M., Gerish Y. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur. Neurol. 2005, 53:125-131.
3. Kurtzke J.F. Multiple sclerosis in time and space-geographic clues to cause. J. Neurovirol. 2000, 6:S134-S140.
4. Etemadifar M., Janghorbani M., Shaygannejad V., Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006, 27:39-44.
5. Hansen T., Skytthe A., Stenager E., Petersen H.C., Brønnum-Hansen H., Kyvik K.O. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 2005, 11:504-510.
6. Kuusisto H., Kaprio J., Kinnunen E., Luukkaala T., Koskenvuo M., Elovaara I. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur. J. Neurol. 2008, 15:1106-1110.
7. McCoy L., Tsunoda I., Fujinami R.S. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006, 39:9-19.
8. Williamson D.M. Studies of multiple sclerosis in communities concerned about environmental exposures. J. Womens Health Larchmt 2006, 15:810-814.
9. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 2005, 14:2019-2026.
10. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
11. Burton P.R., Clayton D.G., Cardon L.R., Craddock N., Deloukas P., Duncanson A., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 2007, 39:1329-1337.
12. Shahbazi M., Ebadi H., Fathi D., Roshandel D., Mahamadhoseeni M., Rashidbaghan A., et al. CCR5-Delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell. Mol. Neurobiol. 2009, 29:1205-1209.
13. Patrucco L., Larriba J., Redal M.A., Rojas J.I., Argibay P.F., Cristiano E. HLA-DRB1 and multiple sclerosis in Argentina. Eur. J. Neurol. 2009, 16:427-429.
14. Ramagopalan S.V., Herrera B.M., Bell J.T., Dyment D.A., Deluca G.C., Lincoln M.R., et al. Parental transmission of HLA-DRB1*15 in multiple sclerosis. Hum. Genet. 2008, 122:661-663.
15. Stankovich J., Butzkueven H., Marriott M., Chapman C., Tubridy N., Tait B.D., et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009, 74:17-21.
16. Duvefelt K., Anderson M., Fogdell-Hahn A., Hillert J. A NOTCH4 association with multiple sclerosis is secondary to HLA-DR*1501. Tissue Antigens 2004, 63:13-20.
17. Shahbazi M., Roshandel D., Ebadi H., Fathi D., Zamani M., Boghaee M., et al. High frequency of the IL-2 -330 T/HLA-DRB1*1501 haplotype in patients with multiple sclerosis. Clin. Immunol. 2010, 137:134-138.
18. Shahbazi M., Ebadi H., Roshandel D., Fathi D., Mahamadhoseeni M., Tahmasebi A., et al. HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in Iranian population. Mult. Scler. 2010, 16:1173-1177.
19. Carroll M.C., Katzman P., Alicot E.M., Koller B.H., Geraghty D.E., Orr H.T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc. Nat. Acad. Sci. 1987, 84:8535-8539.
20. Wilson A.G., di Giovine F.S., Blakemore A.I.F., Duff G.W. Single base polymorphism in the human tumor necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product. Hum. Molec. Genet. 1992, 1:353.
21. Mira J.P., Cariou A., Grall F., Delclaux C., Losser M.R., Heshmati F., et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999, 282:561-568.
22. Padyukov L., Lampa J., Heimburger M., Ernestam S., Cederholm T., Lundkvist I., et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62:526-529.
23. Danis V.A., Millington M., Hyland V., Lawford R., Huang Q., Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis. Markers 1995, 12:127.
24. Huizinga T.W., Westendorp R.G., Bollen E.L., Keijsers V., Brinkman B.M., Langermans J.A., et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J. Neuroimmunol. 1997, 72:149-153.
25. Bendtzen K., Morling N., Fomsgaard A., Svenson M., Jakobsen B., Odum N., Svejgaard A. Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand. J. Immunol. 1988, 28:599-606.
26. Jacob C.O., Fronek Z., Lewis G.D., Koo M., Hansen J.A., McDevitt H.O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 1990, 87:1233-1237.
27. Pociot F., Briant L., Jongeneel C.V., Molvig J., Worsaae H., Abbal M., et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur. J. Immunol. 1993, 23:224-231.
28. Molvig J., Pociot F., Baek L., Worsaae H., Dall W.L., Christensen P., et al. Monocyte function in IDDM patients and healthy individuals. Scand. J. Immunol. 1990, 32:297-311.
29. Mycko M., Kowalski W., Kwinkowski M., Buenafe A.C., Szymanska B., Tronczynska E. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J. Neuroimmunol. 1998, 84:198.
30. Epplen C., Santos E.J., Maueler W., van Helden P., Epplen J.T. On simple repetitive DNA sequences and complex diseases. Electrophoresis 1997, 18:1577.
31. He B., Navikas V., Lundahl J., Soderstrom M., Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J. Neuroimmunol. 1995, 63:143.
32. Kirk C.W., Droogan A.G., Hawkins S.A., McMillan S.A., Nevin N.C., Graham C.A. Tumour necrosis factor microsatellites microsatellites show association with multiple sclerosis. J. Neurol. Sci. 1997, 147:21.
33. Kamali-Sarvestani E., Nikseresht A., Aflaki E., Sarvari J., Gharesi-Fard B. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol. Scand. 2007, 115:161-166.
34. Sarial S., Shokrgozar M.A., Amirzargar A., Shokri F., Radfar J., Zohrevand P., et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran. J. Allergy Asthma Immunol. 2008, 7:37-40.
35. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
36. Shahbazi M., Pravica V., Nasreen N., Fakhoury H., Fryer A.A., Strange R.C., et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002, 359:397-401.
37. Tuwir I., Dunne C., Crowley J., Saddik T., Murphy R., Cassidy L. The relationship between HLA-DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis. Br. J. Ophthalmol. 2007, 91:1288-1292.
38. Marrosu M.G., Murru R., Murru M.R., Costa G., Zavattari P., Whalen M., et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum. Mol. Genet. 2001, 10:2907-2916.
39. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
40. Weinshenker B.G., Wingerchuk D.M., Liu Q., Bissonet A.S., Schaid D.J., Sommer S.S. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 1997, 49:378-385.
41. Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-Lafontaine N., Roland S. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol. 1998, 113:401-406.
42. Anlar B., Alikaöifoglu M., Köse G., Güven A., Gürer Y., Yakut A. Tumor necrosis factor-alpha gene polymorphisms in children with multiple sclerosis. Neuropediatrics 2001, 32:214-216.
43. Braun N., Michel U., Ernst B.P., Metzner R., Bitsch A., Weber F., Rieckmann P. Gene polymorphism at position -308 of the tumor necrosis- factor-alpha (TNF-alpha) in multiple sclerosis and its influence on the regulation of TNF-alpha production. Neurosci. Lett. 1996, 215:75-78.
44. Wu W.S., McClain K.L. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J. Interferon Cytokine Res. 1997, 17:631-635.
45. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 1997, 94:3195-3199.
46. Kubota T., McNamara D.M., Wang J.J., Trost M., McTiernan C.F., Mann D.L., Feldman A.M. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998, 97:2499-2501.
47. Wingerchuk D., Liu Q., Sobell J., Sommer S., Weinshenker B.G. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology 1997, 49:626-628.
48. Barbara J.A., Van ostade X., Lopez A. Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol. Cell Biol. 1996, 74:434-443.
49. Gamble J.R., Harlan J.M., Klebanoff S.J., Vadas M.A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl Acad. Sci. USA 1985, 82:8667-8671.
50. Owens T., Wekerle H., Antel J. Genetic models for CNS inflammation. Nat. Med. 2001, 7:161-166.